62
Pharma & HealthcareBuy
Mirae Asset Healthcare
Mirae Asset · Direct–Growth · rank #4 of 18 by Smart Score
Data updated
Trailing returns
1 Year
22.5%
+19.5% vs index
3 Years
23.9%
+12.3% vs index
5 Years
15.7%
+5.3% vs index
Since launch
22.3%
Year-by-year performance
2021
+28.6%-2.1% vs index
2022
-10.5%-14.3% vs index
2023
+36.1%+9.5% vs index
2024
+41.2%+25.6% vs index
2025
-2.0%-9.7% vs index
2026
+21.7%+23.7% vs index
Why this score
Mirae Asset Healthcare scores 62/100 — #4 of 18 Pharma & Healthcare fund (Buy). It stands out for 3y return and expense ratio — beating 77% of peers on 3y return. The main drag is its volatility (better than only 16% of peers).
Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.
3Y return23.85% · 77th percentile in category
Expense ratio0.61% · 97th percentile in category
Volatility16.93 · 16th percentile in category
Sharpe ratio1.17 · 72nd percentile in category
Alpha3.63 · 22nd percentile in category
5Y return15.66% · 61st percentile in category
Top holdings
1.Sun Pharmaceutical Industries Ltd11.06%
2.Divi's Laboratories Ltd8.71%
3.Torrent Pharmaceuticals Ltd7.47%
4.Apollo Hospitals Enterprise Ltd5.94%
5.Glenmark Pharmaceuticals Ltd5.53%
27 disclosed equity positions · portfolio as of Jul 2026 · weights are % of total corpus.